top of page
​NAYA is pioneering the next generation of cancer therapies by harnessing the transformational potential of two synergistic modalities - astatine-211 (²¹¹At) targeted alpha therapies & bifunctional antibodies - to unlock deeper, more durable responses in patients not responding to current standard-of-care. ​​​​​​​​
Flex-NK™
Bifunctional Antibodies
Our initial strategic focus for both modalities is on addressing the high unmet need for non-responders and those at risk of residual disease in hepatocellular carcinoma (HCC) and multiple myeloma (MM).
bottom of page